<DOC>
	<DOCNO>NCT00071396</DOCNO>
	<brief_summary>The goal clinical research study learn give CAMPATH-1H rituximab shrink slow growth disease patient chronic lymphoid disorder either respond whose disease return treatment standard therapy .</brief_summary>
	<brief_title>Campath-1H Plus Rituximab CD52- CD20- Positive Refractory Relapsed Chronic Lymphoid Disorders</brief_title>
	<detailed_description>Objectives : 1 . To determine efficacy response rate Campath-1H give continuous intravenous infusion follow subcutaneous injection plus rituximab treatment chronic lymphoid disorder refractory conventional therapy , relapse , establish frontline therapy . 2 . To assess safety combination Campath-1H give continuous intravenous infusion follow subcutaneous injection plus rituximab chronic lymphoid disorder express CD52 CD20 cell surface antigens . 3 . To measure level soluble ( ) CD20 sCD52 well level Campath-1H , rituximab antibody complex rituximab/CD20 Campath-1H/CD52 patient chronic lymphoid disorder treat Campath-1H plus rituximab .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Age &gt; /=15 year . 2 . Written informed consent . 3 . Patients chronic lymphoid malignancy either refractory frontline therapy relapse predict probability response le 20 % conventional therapy allogeneic/autologous stem cell transplantation . 4 . The following histology include : Bcell chronic lymphocytic leukemia ( BCLL Bcell CLL ) , Bcell prolymphocytic leukemia ( PLL ) , chronic lymphoid leukemia ( CLL/PLL ) , hairy cell leukemia hairy cell variant , mantle cell leukemia/lymphoma , marginal zone lymphoma/leukemia , splenic lymphoma villous lymphocyte , CLL evidence transformation ( e.g. , Richter 's transformation ) , large granular lymphocytic leukemia ( LGL NKcell type ) . 5 . Patients mentioned histology whose malignant cell population express CD52 CD20 &gt; /= 20 % cell assess flow cytometry immunohistochemistry . Expression CD20 CD52 &lt; 20 % permitted patient receive rituximab alemtuzumab , respectively , within 3 month prior study start . 1 . Patients previously receive Rituximab CAMPATH1H combination exclude . 2 . ECOG performance status &lt; /= 2 . 3 . Serum creatinine &lt; /= 2mg/dL total bilirubin Â£ 2 mg/dL unless due direct infiltration liver kidney malignant cell . 4 . Patients past history anaphylaxis follow exposure rat mouse derive CDRgrafted humanize monoclonal antibody exclude &lt; CDR = complementarity determine region &gt; . 5 . Negative pregnancy test ( serum urine ) female childbearing potential ( nonchildbearing define great one year postmenopausal surgically sterilize ) . 6 . No prior chemotherapy , immunotherapy , hormonal therapy within 2 week prior study start . Hormonal replacement therapy permit . No prior therapy monoclonal antibody least 4 week prior study start . 7 . Patients high risk hepatitis B virus ( HBV ) infection active HBV infection exclude .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CD-52 CD-20 Positive</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
</DOC>